Answers are grounded in this paper and cite their sources.
Review highlights gaps in screening and treatment of familial hypercholesterolaemia in the Asia-Pacific, suggesting improvements.
Familial hypercholesterolaemia (FH) is a genetic disorder, characterised by elevated serum LDL cholesterol levels from birth, and is the most common autosomal dominant disorder affecting up to one in 200 individuals. The majority of FH is expected to be found in the Asia-Pacific region, which comprises 58% of the global population. However, most of the countries in the region are developing nations, which may face challenges in the implementation of detection and treatment strategies. This review aims to describe the current state of FH in this region, including its clinical and genetic epidemiology, and the status of FH screening, detection and treatment. It also aims to identify gaps and strengths in care, and proposes various measures to uplift the management of FH in the Asia-Pacific region.
No takes yet. Share an insight, caveat, or question.
Honda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: